Last reviewed · How we verify
Pemetrexe
At a glance
| Generic name | Pemetrexe |
|---|---|
| Also known as | Alimta |
| Sponsor | Rongjie Tao |
| Target | Serine hydroxymethyltransferase, cytosolic, Folate receptor beta, Folate transporter 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant mesothelioma of pleura
- Non-small cell lung cancer
Common side effects
- Fatigue/Asthenia
- Nausea
- Constipation
- Vomiting
- Diarrhea
- Decreased Appetite/Anorexia
- Rash
- Cough
- Dyspnea
- Pyrexia
- Neutropenia
- Anemia
Serious adverse events
- Acute Kidney Injury
- Pneumonitis
- Pneumonia
Key clinical trials
- Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen (PHASE4)
- To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma (PHASE3)
- Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma (PHASE4)
- Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL） (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pemetrexe CI brief — competitive landscape report
- Pemetrexe updates RSS · CI watch RSS
- Rongjie Tao portfolio CI